iOnctura is a biopharmaceutical company with a pipeline of novel programs that target and modulate key mechanisms driving immuno-suppression in the tumour microenvironment (TME). Checkpoint inhibitors (e.g. anti PD1/PD-L1) have shown remarkable effectiveness for some patients, however in the majority of patients a hostile TME forms a barrier to efficacy. iOnctura aims to overcome this barrier and personalise the use of first generation checkpoint inhibitors through rational biomarker guided combination therapy with its TME targeting programs. It’s collaborations with Merck KGaA and Cancer Research UK allows it to advance these potential therapies quickly to cancer patients. Headquartered in Geneva, Switzerland, iOnctura was founded by Merck Ventures in June 2017.